Har­vard re­searchers hope to bridge the pro­tein gap with new in­sti­tute

Tim­o­thy Springer just un­veiled the new In­sti­tute for Pro­tein In­no­va­tion (IPI), aim­ing to bridge the gap in study­ing pro­tein ther­a­peu­tics. Springer, known for hav­ing a guid­ing hand in biotechs like Mod­er­na Ther­a­peu­tics and Ed­i­tas, kicked in $10 mil­lion from his own pock­et along­side a grant of $5 mil­lion from the Mass­a­chu­setts Life Sci­ences Cen­ter.

While the in­sti­tute will be housed for one year with­in the Har­vard Med­ical School, it will be an in­de­pen­dent en­ti­ty, col­lab­o­rat­ing with aca­d­e­mics and in­dus­try alike to ad­vance pro­tein sci­ence, which co-founder and as­sis­tant pro­fes­sor An­drew Kruse ex­plained to End­points News is “the bridge be­tween the ge­nomics dis­cov­ery, dis­cov­ery of a giv­en tar­get for in­stance and the ac­tu­al de­vel­op­ment of a ther­a­peu­tic tar­get­ing a par­tic­u­lar pro­tein.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER